These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 36762947

  • 1. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study.
    Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo ME.
    Thyroid; 2023 Apr; 33(4):484-491. PubMed ID: 36762947
    [Abstract] [Full Text] [Related]

  • 2. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME.
    Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
    Priantti JN, Rodrigues NMV, de Moraes FCA, da Costa AG, Jezini DL, Heckmann MIO.
    Endocrine; 2024 Oct; 86(1):284-292. PubMed ID: 38709445
    [Abstract] [Full Text] [Related]

  • 4. Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.
    Maurer E, Eilsberger F, Wächter S, Riera Knorrenschild J, Pehl A, Holzer K, Neubauer A, Luster M, Bartsch DK.
    Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1509-1518. PubMed ID: 36637521
    [Abstract] [Full Text] [Related]

  • 5. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME.
    Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.
    Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito KI, Toyoshima M, Hirashima Y, Ueno S, Sugitani I.
    Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
    [Abstract] [Full Text] [Related]

  • 8. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman E, Gill AJ, Ghossein R.
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.
    Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M.
    Thyroid; 2018 Jul; 28(7):945-951. PubMed ID: 29742974
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report.
    Barbaro D, Forleo R, Profilo MA, Lapi P, Giani C, Torregrossa L, Macerola E, Materazzi G.
    Front Endocrinol (Lausanne); 2024 Jul; 15():1389294. PubMed ID: 39045273
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019.
    Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M.
    JAMA Oncol; 2020 Sep 01; 6(9):1397-1404. PubMed ID: 32761153
    [Abstract] [Full Text] [Related]

  • 12. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
    da Silva TN, Rodrigues R, Saramago A, Pires C, Rito M, Horta M, Martins C, Leite V, Cavaco BM.
    Eur J Endocrinol; 2023 Jan 10; 188(1):. PubMed ID: 36651156
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma.
    Yang S, Ji D, Xue F, Chen T, Wang Y, Ji Q.
    Cancer Rep (Hoboken); 2023 Jan 10; 6(1):e1770. PubMed ID: 36535914
    [Abstract] [Full Text] [Related]

  • 14. Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma.
    Kent J, Erwin P, Haraf D, Liao CY, Durham J, Angelos P, Agrawal N, Baird BJ, Madariaga MLL.
    Ann Thorac Surg; 2023 May 10; 115(5):e117-e120. PubMed ID: 35504360
    [Abstract] [Full Text] [Related]

  • 15. Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer.
    Gunda V, Ghosh C, Hu J, Zhang L, Zhang YQ, Shen M, Kebebew E.
    Thyroid; 2023 Oct 10; 33(10):1201-1214. PubMed ID: 37675898
    [Abstract] [Full Text] [Related]

  • 16. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.
    Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME.
    Thyroid; 2017 May 10; 27(5):672-681. PubMed ID: 28068873
    [Abstract] [Full Text] [Related]

  • 17. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma.
    Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas ME.
    JCO Precis Oncol; 2022 Aug 10; 6():e2100504. PubMed ID: 35977347
    [Abstract] [Full Text] [Related]

  • 18. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME.
    Thyroid; 2021 Aug 10; 31(8):1235-1243. PubMed ID: 33599171
    [Abstract] [Full Text] [Related]

  • 19. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.
    Lorimer C, Cheng L, Chandler R, Garcez K, Gill V, Graham K, Grant W, Sardo Infirri S, Wadsley J, Wall L, Webber N, Wong KH, Newbold K.
    Clin Oncol (R Coll Radiol); 2023 Jan 10; 35(1):e60-e66. PubMed ID: 36379836
    [Abstract] [Full Text] [Related]

  • 20. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
    Califano I, Smulever A, Jerkovich F, Pitoia F.
    Rev Endocr Metab Disord; 2024 Feb 10; 25(1):123-147. PubMed ID: 37648897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.